Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07275359 · ClinicalTrials.gov registry record · Phase 1
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
A Phase 1 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT07275359 is a Phase 1 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 45 participants.
The verdict
NCT07275359, a Phase 1 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07275359
The ClinicalTrials.gov registry entry for NCT07275359 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT07275359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07275359 about?
NCT07275359 is a clinical study titled "Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations". The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.
What is the current status of trial NCT07275359?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-09-01. Estimated completion is 2029-10-02.
What interventions are being tested in trial NCT07275359?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT07275359?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.